Susquehanna Fundamental Investments, LLC Fate Therapeutics Inc Transaction History
Susquehanna Fundamental Investments, LLC
- $4.33 Trillion
- Q2 2024
A detailed history of Susquehanna Fundamental Investments, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Susquehanna Fundamental Investments, LLC holds 262,414 shares of FATE stock, worth $493,338. This represents 0.02% of its overall portfolio holdings.
Number of Shares
262,414
Previous 151,121
73.64%
Holding current value
$493,338
Previous $1.11 Billion
22.4%
% of portfolio
0.02%
Previous 0.05%
Shares
6 transactions
Others Institutions Holding FATE
# of Institutions
175Shares Held
115MCall Options Held
53.7KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA13.2MShares$24.8 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$19.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$19 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$10.5 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$9.88 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $182M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...